OverviewSuggest Edit

Immunodiagnostic Systems (IDS) is a global medical diagnostics business dedicated to the development and provision of innovative automated and manual assays. The Company's development focus is in the clinical areas of bone and calcium metabolism, growth, hypertension and chronic kidney disease. Its IDS-iSYS system is designed with the flexibility to accommodate unique and challenging requirements, the IDS-iSYS automation brings testing efficiency and uncompromised quality to specialty immunoassay testing. IDS provides a compact bench top system that fully automates immunoassay testing. IDS has its global headquarters in the UK, and has subsidiaries in the USA, Germany, France, and Denmark. Other markets, including key diagnostic markets of Spain, Italy, Australia, and Japan, are serviced by a network of highly qualified and experienced distributors within each territory.

TypePublic
Founded1977
HQBoldon Colliery, GB
Websiteidsplc.com

Latest Updates

Employees (est.) (Mar 2019)283
Revenue (FY, 2019)£38.5 M(+2%)
Share Price (Nov 2020)£2
Cybersecurity ratingBMore

Key People/Management at Immunodiagnostic Systems

Jaap Stuut

Jaap Stuut

Chief Executive Officer
Burkhard Wittek

Burkhard Wittek

Chairman
Paul Martin

Paul Martin

Finance Director and Company Secretary
Peter Williamson

Peter Williamson

Non-Executive Director
Peter Kaspar

Peter Kaspar

Non-Executive Director
Show more

Immunodiagnostic Systems Office Locations

Immunodiagnostic Systems has offices in Boldon Colliery, Gaithersburg, Scottsdale, Liège and in 19 other locations
Boldon Colliery, GB (HQ)
10 Didcot Way
Liège, BE
Rue Ernest Solvay 101
Markham, CA
50 Valleywood Dr
Kralupy nad Vltavou, CZ
Vodárenská 699
København, DK
International House 5 Center Boulevard København S
Paris, FR
153 Avenue d'Italie
Show all (30)

Immunodiagnostic Systems Financials and Metrics

Immunodiagnostic Systems Revenue

Embed Graph
View revenue for all periods
Immunodiagnostic Systems's revenue was reported to be £38.51 m in FY, 2019
GBP

Revenue (FY, 2019)

38.5m

Gross profit (FY, 2019)

16.7m

Gross profit margin (FY, 2019), %

43.4%

Net income (FY, 2019)

796.0k

EBITDA (FY, 2019)

4.9m

EBIT (FY, 2019)

429.0k

Market capitalization (13-Nov-2020)

58.9m

Closing stock price (13-Nov-2020)

2.0

Cash (31-Mar-2019)

27.7m
Immunodiagnostic Systems's current market capitalization is £58.9 m.
GBPFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

38.3m40.0m37.9m38.5m

Revenue growth, %

(16%)5%(5%)

Cost of goods sold

15.8m20.1m19.9m21.8m

Gross profit

22.5m19.9m18.0m16.7m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

446.7k885.1k959.8k3.0m4.5m5.3m6.4m11.0m19.6m26.7m23.7m26.6m31.5m28.5m27.7m

Accounts Receivable

922.8k1.3m1.6m4.0m4.4m6.4m7.8m3.6m7.3m5.2m5.4m5.3m6.6m7.4m

Inventories

762.6k805.2k914.6k6.2m5.7m6.4m8.5m7.5m5.9m6.5m6.8m7.5m7.6m8.4m7.8m

Current Assets

2.5m3.3m4.0m14.0m19.4m23.2m27.8m27.4m35.9m42.5m40.7m43.2m48.9m48.4m47.5m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

212.3k916.9k1.6m2.8m4.2m8.1m12.9m4.7m7.8m7.0m2.4m(32.2m)3.0m1.2m796.0k

Cash From Operating Activities

248.2k1.2m2.1m445.0k5.3m9.7m16.5m14.3m18.4m12.3m8.8m8.2m8.4m2.5m5.8m

Dividends Paid

133.4k202.0k360.3k436.3k559.0k708.0k215.0k866.0k2.5m876.0k353.0k1.2m500.0k

Cash From Financing Activities

1.5m(286.7k)(688.7k)24.9m1.9m(1.9m)(5.5m)(2.1m)(5.0m)854.0k(2.6m)(985.0k)(537.0k)(1.4m)(2.0m)
GBPFY, 2005

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

2.4 x
Show all financial metrics

Immunodiagnostic Systems Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Immunodiagnostic Systems Online and Social Media Presence

Embed Graph

Immunodiagnostic Systems Blogs

The new automated TGS COVID-19 IgM assay is now available!

To order the automated TGS COVID-19 IgM or IgG assays, or the ErbaLisa® COVID-19 IgM or IgG ELISA assays please contact your local sales support team: Or your local sales representative: Germany Customer Service Tel: +49 69 26019 0960 Email:customercare.de@idsplc.com France Customer Service Tel: +33 1 40 77 04 60 Email:advfrance@idsplc.com…

Manufacturing Services Case Study – SARS-CoV-2 Antibody Elisa with The Binding Site

IDS were approached by The Binding Site (TBS) in May 2020 to provide manufacturing support for their SARS-CoV-2 antibody Elisa test which TBS had started developing in collaboration with the University of Birmingham.   The team at IDS, based in Boldon UK, worked with TBS to understand the performanc…

Launch of the IDS Cortisol assay on the IDS-iSYS Multi-Discipline Automated System

The IDS Cortisol assay is a fully automated CLIA assay for the quantitative determination of cortisol in human serum and plasma samples. Measurement of Cortisol concentrations can be used to assist in the diagnosis and treatment of disorders of the adrenal gland, such as hypo- and hyper-cortisolism,…

The new automated COVID-19 IgG assay is now available for sale!

To order our automated COVID-19 IgG assay please contact your local sales support team: Or your local sales representative Germany Customer Service Tel: +49 69 26019 0960 Email:customercare.de@idsplc.com France Customer Service Tel: +33 1 40 77 04 60 Email:advfrance@idsplc.com UK Customer Service Tel: +44 (0) 191 519 6155 Email:salessupport.uk@idsplc.com…

The IDS Automated COVID-19 IgG Antibody Test

The new automated COVID-19 IgG assay has now achieved its CE marking and is expected to be available for sale by the end of June. The COVID-19 IgG assay, a product of our partnership with Technogenetics, is designed to run on our IDS-iSYS Multi-Discipline Automated System, to reduce the testing time…

Manufacturing Support for COVID-19

Manufacturing Support As the world struggles to contain the novel coronavirus (COVID-19) outbreak, it becomes clear that diagnostics test availability is a key constraint. To support our healthcare systems with this challenge, we need to rapidly move production resources into this area. We at Immuno…
Show more

Immunodiagnostic Systems Frequently Asked Questions

  • When was Immunodiagnostic Systems founded?

    Immunodiagnostic Systems was founded in 1977.

  • Who are Immunodiagnostic Systems key executives?

    Immunodiagnostic Systems's key executives are Jaap Stuut, Burkhard Wittek and Paul Martin.

  • How many employees does Immunodiagnostic Systems have?

    Immunodiagnostic Systems has 283 employees.

  • What is Immunodiagnostic Systems revenue?

    Latest Immunodiagnostic Systems annual revenue is £38.5 m.

  • What is Immunodiagnostic Systems revenue per employee?

    Latest Immunodiagnostic Systems revenue per employee is £136.1 k.

  • Who are Immunodiagnostic Systems competitors?

    Competitors of Immunodiagnostic Systems include Abaxis, Lynn Medical and LifeHealthcare.

  • Where is Immunodiagnostic Systems headquarters?

    Immunodiagnostic Systems headquarters is located at 10 Didcot Way, Boldon Colliery.

  • Where are Immunodiagnostic Systems offices?

    Immunodiagnostic Systems has offices in Boldon Colliery, Gaithersburg, Scottsdale, Liège and in 19 other locations.

  • How many offices does Immunodiagnostic Systems have?

    Immunodiagnostic Systems has 30 offices.